Source-grounded facts extracted from COGNITION THERAPEUTICS INC's SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
COGNITION THERAPEUTICS INC shareholders approved Ratification of Independent Registered Public Accountants at the 2026-06-17 meeting.
“The appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the 2026 fiscal year was ratified, as follows: For Against Abstentions Broker Non-Votes 49,039,407 126,951 643,517 0”
COGNITION THERAPEUTICS INC shareholders approved Election of Class II Directors at the 2026-06-17 meeting.
“Each of Aaron Fletcher, Ph.D., and Lisa Ricciardi were elected to the Board of Directors as Class II directors to serve until the Company’s 2029 Annual Meeting of Stockholders and until their successors, if any, are elected or appointed, or their earlier death, resignation, retirement, disqualification or removal as follows: Name For Withheld Broker Non-Votes Aaron Fletcher, Ph.D. 15,093,537 680,677 34,035,661 Lisa Ricciardi 15,094,238 679,976 34,035,661”
COGNITION THERAPEUTICS INC reported the first quarter ended March 31, 2026 results: net income $4.6 million, EPS $(0.05) per basic and diluted share.
“expenses was driven primarily by lower stock compensation, compensation and professional fees. Cognition Therapeutics, Inc. www.cogrx.com The Company reported a net loss of $4.6 million, or $(0.05) per basic and diluted share for the first quarter ended March 31, 2026, compared to a net loss of $8.5 million, or $(0.14) per basic and diluted share for the same”
COGNITION THERAPEUTICS INC reported the year ended December 31, 2025 results: net income $23.5 million, or $(0.32) per basic and diluted share, EPS $(0.32) per basic and diluted share.
“$12.3 million for 2024. The change in general and administrative expenses was driven primarily by reduced stock-based compensation expenses. The Company reported a net loss of $23.5 million, or $(0.32) per basic and diluted share for the year ended December 31, 2025, compared to a net loss of $34.0 million, or $(0.86) per basic and diluted share for 2024. Conference”
COGNITION THERAPEUTICS INC terminated Controlled Equity Offering Sales Agreement with Cantor Fitzgerald & Co. and B. Riley Securities, Inc. (effective 2025-12-16).
“On December 16, 2025, the Company delivered written notice to B. Riley to terminate the Previous Sales Agreement, effective as of December 18, 2025, pursuant to Section 12(b) thereof.”
COGNITION THERAPEUTICS INC entered into Open Market Sale Agreement with Jefferies LLC valued at up to an aggregate of $75,000,000 (effective 2025-12-18).
“(the “ Company”) entered into an Open Market Sale Agreement SM (the “Sales Agreement”) with Jefferies LLC (“Jefferies”), pursuant to which the Company may sell, from time to”
COGNITION THERAPEUTICS INC reported first quarter ended March 31, 2024 results: net income $9.2 million, EPS $(0.27) per basic and diluted share.
“The Company reported a net loss of $9.2 million, or $(0.27) per basic and diluted share for the first quarter ended March 31, 2024”
COGNITION THERAPEUTICS INC reported the year ended December 31, 2023 results: net income $25.8 million, EPS $(0.86) per basic and diluted share.
“The Company reported a net loss of $25.8 million, or $(0.86) per basic and diluted share for the year ended December 31, 2023”
COGNITION THERAPEUTICS INC entered into Underwriting Agreement with Titan Partners Group LLC, a division of American Capital Partners, LLC (effective 2024-03-11).
“On March 11, 2024, Cognition Therapeutics, Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Titan Partners Group LLC, a division of American Capital Partners, LLC (the “Underwriter”), pursuant to which the Company agreed to issue and sell to the Underwriter, in a public offering (the “Offering”), 6,571,428 shares (the “Shares”) of the Company’s common stock, par value $0.001 per share (“Common Stock”) at a public offering price of $1.75 per share (the “Offering Price”).”
COGNITION THERAPEUTICS INC reported the year ended December 31, 2023 results: net income approximately $25.6 million.
“Preliminary unaudited consolidated operating results for the year ended December 31, 2023 and certain preliminary financial condition information as of December 31, 2023 are as follows: · Net loss for the year ended December 31, 2023 is expected to be approximately $25.6 million.”
COGNITION THERAPEUTICS INC reported third quarter ended September 30, 2023 results: net income net loss of $6.7 million, EPS $(0.22) per basic and diluted share.
“The Company reported a net loss of $6.7 million or $(0.22) per basic and diluted share for the third quarter ended September 30, 2023, compared to a net loss of $6.6 million or $(0.29) per basic and diluted share during the same period in 2022.”
COGNITION THERAPEUTICS INC reported the second quarter ended June 30, 2023 results: net income net loss of $4.7 million or $(0.16) per basic and diluted share.
“The Company reported a net loss of $4.7 million or $(0.16) per basic and diluted share for the second quarter ended June 30, 2023, compared to a net loss of $5.8 million or $(0.25) per basic and diluted share during the same period in 2022.”
COGNITION THERAPEUTICS INC shareholders approved Ratification of Independent Registered Public Accountants. at the 2023-06-09 meeting.
“Proposal 2 – Ratification of Independent Registered Public Accountants. The appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the 2023 fiscal year was ratified, as follows: For Against Abstentions Broker Non-Votes 19,173,712 13,668 43,820 0”
COGNITION THERAPEUTICS INC shareholders approved Election of Class II Directors. at the 2023-06-09 meeting.
“Proposal 1 – Election of Class II Directors. Each of Aaron Fletcher and Lisa Ricciardi were elected to the Board of Directors as Class II directors to serve until the Company’s 2026 Annual Meeting of Stockholders and until their successors, if any, are elected or appointed, or their earlier death, resignation, retirement, disqualification or removal as follows: Name For Withheld Broker Non-Votes Aaron Fletcher 11,466,658 551,940 7,212,602 Lisa Ricciardi 10,596,682 1,421,916 7,212,602”
COGNITION THERAPEUTICS INC reported first quarter ended March 31, 2023 results: net income a net loss of $6.2 million, EPS $(0.21) per basic and diluted share.
“The Company reported a net loss of $6.2 million, or $(0.21) per basic and diluted share for the first quarter ended March 31, 2023, compared to a net loss of $3.8 million or $(0.17) per basic and diluted share during the same period in 2022.”
Andrew Einhorn departed as Interim Chief Financial Officer at COGNITION THERAPEUTICS INC.
“Mr. Doyle will succeed Mr. Andrew Einhorn, who has served as the Company’s Interim Chief Financial Officer since August 2022.”
John Doyle was appointed as Chief Financial Officer at COGNITION THERAPEUTICS INC.
“On May 1, 2023, Cognition Therapeutics, Inc. (the “ Company ”) announced the appointment of John Doyle as Chief Financial Officer of the Company, effective May 1, 2023.”
COGNITION THERAPEUTICS INC reported the year ended December 31, 2022 results: net income $21.4 million, EPS $0.91 per basic and diluted share.
“For the year ended December 31, 2022, Cognition Therapeutics reported a net loss of $21.4 million, or $0.91 per basic and diluted share, compared to a net loss of $11.7 million, or $3.13 per basic and diluted share for 2021.”
COGNITION THERAPEUTICS INC reported the year ended December 31, 2022 results: net income approximately $21.4 million.
“Preliminary unaudited operating results for the year ended December 31, 2022 and certain preliminary financial condition information as of December 31, 2022 are as follows: · Net loss for the year ended December 31, 2022 is expected to be approximately $21.4 million. · As of December 31, 2022, the Company had approximately $41.6 million in cash and cash equivalents.”
COGNITION THERAPEUTICS INC entered into Purchase Agreement with Lincoln Park Capital Fund, LLC valued at up to $35,000,000 (effective 2023-03-10).
“Cognition Therapeutics, Inc. (the “Company”) entered into a purchase agreement (the “Purchase Agreement”) with Lincoln Park Capital Fund, LLC (“Lincoln Park”), which provides that, upon the terms and subject to the conditions and limitations set forth therein, the Company has the right, but not the obligation, to sell to Lincoln Park up to $35,000,000 of shares of the Company’s common stock”
COGNITION THERAPEUTICS INC entered into Sales Agreement with Cantor Fitzgerald & Co. and B. Riley Securities, Inc. valued at up to $40 million (effective 2022-12-23).
“On December 23, 2022, Cognition Therapeutics, Inc. (the “Company”), entered into a Controlled Equity Offering SM Sales Agreement (the “Sales Agreement”) with Cantor Fitzgerald & Co. and B. Riley Securities, Inc. (each, an “Agent”, and together the “Agents”), under which the Company may offer and sell, from time to time at its sole discretion, shares of its common stock, par value $0.001 per share (the “Shares”), having an aggregate offering price of up to $40 million through or to the Agents.”
COGNITION THERAPEUTICS INC reported third quarter ended September 30, 2022 results: net income $6.6 million, EPS $0.29 per share.
“Net loss attributable to common stockholders for the third quarter ended September 30, 2022, was $6.6 million or $0.29 per share.”
COGNITION THERAPEUTICS INC entered into Underwriting Agreement with Cantor Fitzgerald & Co. valued at 5,000,000 shares of common stock at $1.20 per share (effective 2022-11-10).
“On November 10, 2022, Cognition Therapeutics, Inc. (the “Company”) entered into an Underwriting Agreement (the “Underwriting Agreement”) with Cantor Fitzgerald & Co., as representative of the several underwriters named in Schedule A thereto (the “Underwriters”), relating to the public offering (the “Offering”) of 5,000,000 shares of the Company’s common stock, $0.001 par value per share (“Common Stock”), at a price to the public of $1.20 per share (the “Offering Price”), less underwriting discounts and commissions.”
Andrew Einhorn was appointed as Interim Chief Financial Officer at COGNITION THERAPEUTICS INC.
“the board of directors of the Company appointed Andrew Einhorn as Interim Chief Financial Officer, effective as of the Effective Date.”
James O'Brien departed as Chief Financial Officer at COGNITION THERAPEUTICS INC.
“the Company determined that James O’Brien, the Company’s Chief Financial Officer, will be leaving the Company as of August 12, 2022”
Mark H. Breedlove resigned as Director at COGNITION THERAPEUTICS INC.
“On October 29, 2021, Mark H. Breedlove notified the Board that he intends to resign as a member of the Board, effective December 31, 2021.”
Ellen B. Richstone was appointed as Class I Director at COGNITION THERAPEUTICS INC.
“Effective November 1, 2021, in connection with the Board Increase, the Board appointed Ellen B. Richstone to serve as a Class I member of the Board”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.